CD123 CAR T-cell therapy / Tianjin First Central Hospital - LARVOL DELTA

Synthetic Notch CD123 and CLL1 chimeric antigen receptor T-cells (CAR-T) target acute myeloid leukemia and reduce off-tumor effects associated with CLL1 CAR-T cells. (PubMed, Mol Biomed) - "Increased cytokine production in vitro indicated stronger T-cell activation but also suggested the need for careful evaluation of potential cytokine-related toxicity. These findings indicate that SynNotch dual-antigen-gated CAR-T cells may provide a more specific and potentially safer therapeutic strategy for relapsed/refractory AML."

IO biomarker • Journal • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Neutropenia • Oncology • CD123 • IL3RA

Efficacy analysis of CAR-T cells against CD123-positive malignant tumors and exploration of the feasibility of combination therapy with venetoclax. (PubMed, Ann Hematol) - P=N/A | "Multi-omics analysis combining transcriptomic and metabolomic sequencing identified distinct alterations in key metabolic pathways between CD123 CAR-T cells and V-CD123 CAR-T cells. We propose that low-dose venetoclax combined with CD123 CAR-T cells enhances cytotoxicity, which may be attributed to metabolic optimization in CAR-T cells."

Journal • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • Solid Tumor • CD123 • GLI2 • IL3RA